Quanterix (QTRX) Competitors $10.93 -0.09 (-0.82%) (As of 09:48 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends QTRX vs. PACB, FLDM, HBIO, AXDX, TRNS, CTKB, EYPT, LAB, AEHR, and NAUTShould you be buying Quanterix stock or one of its competitors? The main competitors of Quanterix include Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO), Accelerate Diagnostics (AXDX), Transcat (TRNS), Cytek Biosciences (CTKB), EyePoint Pharmaceuticals (EYPT), Standard BioTools (LAB), Aehr Test Systems (AEHR), and Nautilus Biotechnology (NAUT). Quanterix vs. Pacific Biosciences of California Fluidigm Harvard Bioscience Accelerate Diagnostics Transcat Cytek Biosciences EyePoint Pharmaceuticals Standard BioTools Aehr Test Systems Nautilus Biotechnology Pacific Biosciences of California (NASDAQ:PACB) and Quanterix (NASDAQ:QTRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, community ranking, valuation, profitability, risk, earnings, dividends and media sentiment. Which has more risk and volatility, PACB or QTRX? Pacific Biosciences of California has a beta of 2.01, meaning that its share price is 101% more volatile than the S&P 500. Comparatively, Quanterix has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Does the media favor PACB or QTRX? In the previous week, Quanterix had 3 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 12 mentions for Quanterix and 9 mentions for Pacific Biosciences of California. Quanterix's average media sentiment score of 0.30 beat Pacific Biosciences of California's score of 0.14 indicating that Quanterix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacific Biosciences of California 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Quanterix 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings and valuation, PACB or QTRX? Quanterix has lower revenue, but higher earnings than Pacific Biosciences of California. Quanterix is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPacific Biosciences of California$200.52M2.35-$306.73M-$1.46-1.18Quanterix$122.37M3.43-$32.33M-$1.05-10.41 Is PACB or QTRX more profitable? Quanterix has a net margin of -30.71% compared to Pacific Biosciences of California's net margin of -227.69%. Quanterix's return on equity of -11.52% beat Pacific Biosciences of California's return on equity.Company Net Margins Return on Equity Return on Assets Pacific Biosciences of California-227.69% -42.71% -15.38% Quanterix -30.71%-11.52%-9.47% Do analysts rate PACB or QTRX? Pacific Biosciences of California presently has a consensus price target of $3.63, indicating a potential upside of 110.68%. Quanterix has a consensus price target of $23.25, indicating a potential upside of 112.72%. Given Quanterix's stronger consensus rating and higher probable upside, analysts plainly believe Quanterix is more favorable than Pacific Biosciences of California.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pacific Biosciences of California 0 Sell rating(s) 8 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.47Quanterix 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Do insiders and institutionals believe in PACB or QTRX? 86.5% of Quanterix shares are owned by institutional investors. 2.4% of Pacific Biosciences of California shares are owned by company insiders. Comparatively, 6.9% of Quanterix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community believe in PACB or QTRX? Pacific Biosciences of California received 181 more outperform votes than Quanterix when rated by MarketBeat users. Likewise, 66.86% of users gave Pacific Biosciences of California an outperform vote while only 61.56% of users gave Quanterix an outperform vote. CompanyUnderperformOutperformPacific Biosciences of CaliforniaOutperform Votes45066.86% Underperform Votes22333.14% QuanterixOutperform Votes26961.56% Underperform Votes16838.44% SummaryQuanterix beats Pacific Biosciences of California on 12 of the 18 factors compared between the two stocks. Ad DarwinNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Get Quanterix News Delivered to You Automatically Sign up to receive the latest news and ratings for QTRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QTRX vs. The Competition Export to ExcelMetricQuanterixAnalytical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$419.49M$5.28B$5.07B$8.80BDividend YieldN/A0.47%4.99%4.07%P/E Ratio-10.417.1889.5613.60Price / Sales3.433.961,224.8087.40Price / CashN/A41.0639.4536.27Price / Book1.192.436.976.33Net Income-$32.33M$515,312.50$119.04M$225.93M7 Day Performance-8.31%-5.87%-1.78%-0.96%1 Month Performance-11.43%-8.41%-3.59%1.06%1 Year Performance-53.67%-17.17%31.64%26.59% Quanterix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QTRXQuanterix2.4285 of 5 stars$10.93-0.8%$23.25+112.7%-52.5%$419.49M$122.37M-10.41460PACBPacific Biosciences of California1.5162 of 5 stars$1.72+0.0%$3.63+110.7%-80.0%$471.20M$200.52M0.00730Analyst RevisionFLDMFluidigmN/AN/AN/AN/A$283.76M$130.58M-4.76615HBIOHarvard Bioscience1.5634 of 5 stars$2.14-0.9%N/A-48.8%$93.35M$112.25M-6.55490Positive NewsAXDXAccelerate Diagnostics2.4379 of 5 stars$1.63-4.1%$1.00-38.7%-67.0%$40.82M$12.06M0.00134TRNSTranscat2.9676 of 5 stars$104.02+1.2%$127.25+22.3%+7.5%$956.98M$259.48M51.931,104Positive NewsCTKBCytek Biosciences2.884 of 5 stars$6.09-0.7%$9.17+50.5%+0.8%$784.45M$193.01M0.00500Short Interest ↓News CoverageEYPTEyePoint Pharmaceuticals2.2894 of 5 stars$9.01+0.7%$28.00+210.8%+26.6%$614.93M$46.02M0.00120LABStandard BioTools3.2166 of 5 stars$1.60-0.6%$2.88+79.7%-29.1%$595.62M$106.34M0.00620AEHRAehr Test Systems2.1758 of 5 stars$11.34+0.6%$25.00+120.5%-56.6%$336.00M$66.22M11.5090NAUTNautilus Biotechnology1.7398 of 5 stars$2.32-0.9%$4.50+94.0%-15.8%$291.30MN/A0.00130 Related Companies and Tools Related Companies PACB Alternatives FLDM Alternatives HBIO Alternatives AXDX Alternatives TRNS Alternatives CTKB Alternatives EYPT Alternatives LAB Alternatives AEHR Alternatives NAUT Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:QTRX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quanterix Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quanterix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
